Renaissance BioScience files PCT Patent Application for Yeast-based RNA Bioactive Molecule Production and Delivery Technology Platform
VANCOUVER, British Columbia, May 16, 2019 (GLOBE NEWSWIRE) -- Renaissance BioScience Corp., a leading biological engineering company, is pleased to announce the filing on May 8, 2019 of a PCT patent application for a yeast platform technology that produces and delivers RNA bioactive molecules.
Renaissance BioScience is developing a yeast-based RNAi production and delivery technology platform for use in biocontrol and/or biotherapeutic applications. Use of this platform technology as a biopesticide may augment or replace industrial chemical pesticides in many different agricultural applications, as well as form the basis of an animal and human biotherapeutics production and delivery platform.
“Our patent application is a significant milestone event in the research and development of our yeast-based RNAi production and delivery technology,” said Dr. Matthew Dahabieh, Chief Science Officer for Renaissance BioScience. “Although much work remains to be done, this is an exciting achievement for RNAi technology in biocontrol, biopesticides and biotherapeutics, and we look forward to advancing our technology.”
Using a yeast-based platform is favourable, as yeast produced and delivered RNAi effectors are protected from degradation in any given application environment. Moreover, yeast can be administered easily by feeding, and yeast is consumed by many insect, livestock and aquaculture species, as well as humans. Additionally, yeast is easy and inexpensive to produce, and is a ubiquitous, safe and well-understood microorganism.
About RNA Interference
RNA interference (RNAi) is a well-characterized biological process that uses inherent cellular machinery to inhibit expression of target genes in an organism in response to treatment with specific RNA effectors. RNAi is a promising modality for biocontrol and biotherapeutics and has broad potential applications within the agricultural and pharmaceutical industries. However, current RNAi technologies face significant challenges in terms of delivery mechanisms that can provide consistent stability and targeting of RNAi effectors, especially in agricultural applications.
About Renaissance BioScience Corp.
Renaissance BioScience Corp., based in Vancouver, Canada, is a privately held, global, industry leading biological engineering company. Renaissance develops functional, market-ready microorganisms for the global food and beverage, agriculture, chemicals, and healthcare industries. Detailed information about Renaissance BioScience can be accessed at www.renaissancebioscience.com.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Maha Energy AB (publ) (“Maha” or the “Company”) Announces Filing of Second Quarter Report and Live Webcast26.8.2019 01:00:00 CEST | Press release
Maha Energy AB (publ) Strandvagen 5A SE-114 51 Stockholm www.mahaenergy.ca Press release Stockholm 26 August 2019 Maha Energy AB Announces Filing of Second Quarter Report & Live Webcast Maha Energy AB (publ) (“Maha” or the “Company”) is pleased to announce its second quarter results. The report is attached to this press release and available on the Company’s website at www.mahaenergy.ca Second Quarter 2019 Daily oil & gas production for Q2 2019 averaged 2,739 BOEPD (Q2 2018: 1,429 BOEPD). Revenue of USD 14.1 million (Q2 2018: USD 7.9 million) Operating netback of USD 10.7 million or USD 43.30 per BOE (Q2 2018: USD 5.1 million or USD 39.22 per BOE) EBITDA of USD 9.2 million (Q2 2018: USD 4.0 million) Net result of USD 6.2 million (Q2 2018: USD 1.9 million) Basic and diluted Earnings per share of USD 0.06 (Q2 2018: USD 0.02) Six Months Ended 30 June 2019 Daily oil & gas production for H1 2019 2,704 BOEPD (H1 2018: 1,595 BOEPD). Revenue of USD 25.8 million (H1 2018: USD 16.5 million) Oper
Cargotec appoints Päivi Koivisto as Vice President, Sustainability25.8.2019 09:00:00 CEST | Press release
CARGOTEC CORPORATION, PRESS RELEASE, 25 AUGUST 2019 AT 10:00 AM (EEST) Cargotec appoints Päivi Koivisto (M.Sc. Env. Tech., eMBA) as Vice President, Sustainability as of 23 September 2019. She will be responsible for Cargotec's corporate Sustainability function. Koivisto joins Cargotec from UPM Communications Papers where she worked as Director, Sustainability. Päivi Koivisto reports to Cargotec's SVP Communications Carina Geber-Teir. "At Cargotec, we firmly believe that a profitable and sustainable business requires ethical and sustainable ways of working. Päivi has a solid track record from an industry where these issues have been developed with determination for years. I am pleased to welcome Päivi to Cargotec. Her passion for and expertise in sustainability makes her a perfect fit to drive Cargotec’s sustainability actions to an increasingly higher level," says Carina Geber-Teir. For more information, please contact: Carina Geber-Teir, SVP Communications, Cargotec, carina.geber-teir
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration23.8.2019 22:01:00 CEST | Press release
Foster City, Calif. and Mechelen, Belgium; 23 August 2019; 22.01 CET; regulated information – Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced the closing of the global research and development collaboration agreement signed on 14 July 2019. This agreement has received clearance from the U.S. Federal Trade Commission under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and merger control approval from the Austrian Federal Competition Authority. Under the terms of the agreement, the closing of this transaction triggers an upfront license fee payment of $3.95 billion by Gilead to Galapagos. In addition, Gilead has made an equity investment in Galapagos of approximately $1.1 billion (or approximately €960 million) by subscribing for new shares at a price of €140.59 per share, including issuance premium. As a result, Gilead now owns 13,589,686 ordinary shares of Galapagos, representing approximately 22 percent of the currently outsta
EVS Broadcast Equipment strikes major deal with NEP to upgrade their US production activities23.8.2019 18:00:00 CEST | Press release
Publication on August 23 2019, 06:00 P.M. CET Regulated information – Privileged information EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS STRIKES MAJOR DEAL WITH NEP TO UPGRADE THEIR US PRODUCTION ACTIVITIES EVS Broadcast Equipment, the leading provider of live production solutions, today announces that NEP is investing over $8m to deploy the next generation EVS live video production server as part of their US inventory. Liège, Belgium, August 23, 2019 EVS, the leading provider of live production solutions, has been selected by NEP, an international production company serving live broadcasting throughout the world, to deliver a major upgrade and upscale of their production facilities. The deal represents the acquisition of EVS’ XT-VIA next-generation live production servers, as well as the deployment of LSM replay controllers, IPDirector content management solutions and other infrastructure systems. All new systems will be installe
Clinical data on Idorsia's pipeline compounds will be presented at the European Society of Cardiology Congress 201923.8.2019 17:35:00 CEST | Press release
Allschwil, Switzerland – August 23, 2019 Idorsia Ltd (SIX: IDIA) today announced that data from Phase 2 studies with aprocitentan, a new dual endothelin receptor antagonist, and selatogrel, a highly-selective P2Y12 receptor antagonist, will be shared during the European Society of Cardiology (ESC) Congress 2019 in Paris, France. Idorsia’s aprocitentan An oral presentation entitled "Efficacy and safety of various doses of the new dual endothelin receptor antagonist aprocitentan in the treatment of hypertension", will be part of the "Drug treatment in hypertension - New insights" session with a focused discussion with the lead author, Dr Parisa Danaietash from Idorsia, at 09:54 on August 31, 2019. The abstract can be found online. Idorsia’s selatogrel An oral presentation entitled "Selatogrel, a novel P2Y12 inhibitor for emergency use, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients", will be part of th
Millicom - H1 2019 Consolidated Financial Statements23.8.2019 16:53:00 CEST | Press release
Millicom’s H1 2019 Consolidated Financial Statements Luxembourg, August 23, 2019— Millicom, a leading provider of cable and mobile services operating under the TIGO brand in Latin America, has published its H1 2019 consolidated financial statements. Contents include: • Management Report • Responsibility Statement • Review Report of the Independent Auditors • Unaudited Interim Condensed Consolidated Financial Statements -END- For further information, please contact Press: Vivian Kobeh, Corporate Communications Director +1 786-628-5300 email@example.com Investors: Michel Morin, VP Investor Relations +1 786-628-5270 firstname.lastname@example.org Sarah Inmon, Investor Relations Manager +1-786-628-5303 email@example.com About Millicom Millicom (NASDAQ U.S.: TIGO, Nasdaq Stockholm: TIGO_SDB) is a leading provider of cable and mobile services dedicated to emerging markets in Latin America and Africa. Millicom sets the pace when it comes to providing high-speed broadband and innovation around T